Much research into new medicines is now taking place in smaller companies or in departments with limited budgets for expensive and slow High Throughput Screens. Furthermore, screening capacity for certain target classes can be limited by automated screening technology capabilities. Hit discovery therefore has to use smarter, cheaper and more effective strategies; even large companies need to contain costs and make use of faster hit discovery processes.
This meeting will examine opportunities for conducting hit discovery more efficiently, from the creation of lead-like collections, knowledge based design of specific protein ligands, to exploiting informatics in directing compound synthesis choices. It will demonstrate future strategies being adopted by both small and large organisations, new initiatives such as the European Lead Factory, as well as considering novel approaches.
Catherine Nicholson (send an email)
Posters: Thursday, May 1, 2014
Finding quality leads from screens: what to screen, how to screen it?
Darren Green, GlaxoSmithKline, U.K.
Collaborative Hit ID in academia-industry alliances
Martin Swarbick, Cancer Research UK, U.K.
IMI European lead factory: New opportunities for drug discovery
Phil Jones, Innovative Medicine’s Initiative, U.K.
Lunch break and Poster Session
Using Bioactivity Databases and Computational Algorithms: From Ligand Design to Mode-of-Action Analysis
Andreas Bender, University of Cambridge, U.K.
Off-Rate Screening. An efficient method to kinetically sample hit to lead chemical space in unpurified reactions
James Murray,Vernalis, U.K.
Rational design of multiple-acting ligands
Ola Engkvist, AstraZeneca, Sweden
EKO and EKOS: A new perspective on discovery of small molecules to perturb protein-protein interactions
Kevin Burgess, University of Florida, USA